A brake on the brake
Myostatin limits muscle growth. That is its physiological job: a negative regulator that keeps tissue from expanding without constraint. Follistatin binds myostatin and related proteins, which means it acts on the limiter rather than on growth itself.
The number in the name refers to an isoform. Follistatin exists in several lengths produced by different processing of the same gene, and 344 is one of them. Studies using different isoforms are not straightforwardly comparable.
Someone asking what is follistatin 344 is usually really asking whether the dramatic animal results transfer to an administered protein, and that is the one question the literature does not settle. The mechanism is well described; the leap to what injection would do in an adult is not.
Why the animal work travels badly
The striking results in this area come from genetic models: animals engineered to overexpress follistatin, or lacking functional myostatin. Those are powerful demonstrations that the pathway matters, and they say very little about what administering a protein would do.
A genetic model changes a system from conception. Introducing a protein into an adult organism is a different experiment with different constraints, and conflating the two is the single most common error in how this compound is discussed.
There is a second reason the genetic work travels badly, and it concerns quantity rather than timing. An engineered animal produces the protein continuously, in its own tissues, at whatever level the modification sets. An administered dose is an external amount that arrives and then clears. Those are different exposures to the same molecule, and the first tells you very little about the second.
| Type | Glycoprotein |
| Length | 344 residues, one isoform of several |
| Mechanism | Binds myostatin and related proteins |
| Research models | Largely genetic overexpression models |
| Format | Pre-filled peptide pen |
| Purity | ≥ 99% (HPLC) |
| Evidence base | Animal work, mostly genetic rather than administered |
| Category | Research use only |
A description of the product, not a summary of findings.
A protein, with what that implies
At 344 residues this is a protein rather than a peptide, and considerably larger than anything else in the catalogue. Size drives stability, handling and how a molecule behaves in solution.
It also makes analysis harder. Confirming the identity and integrity of a glycoprotein is a more involved question than confirming a short sequence, which is worth knowing when you read any certificate for this material.
Glycosylation is part of why the analysis is harder. Sugar groups attached to a protein vary, so material can be the right sequence while differing in what is hung off it, and that is not a question a purity line answers. It is worth holding in mind when you read any certificate of analysis for material of this size. The published work sits behind the record on PubMed.
Why the muscle pages keep bundling different things
The muscle research area repeatedly bundles compounds that work in unrelated ways. Follistatin acts on a growth limiter; a repair peptide such as TB-500 works on tissue turnover; a growth hormone secretagogue works through an entirely separate axis. Grouping them by goal hides how different the mechanisms are.
Size also shapes what a batch looks like. The pen holds a smaller quantity than the shorter peptides because the amounts used in research differ, and the release testing behind it follows the same quality standard applied to everything else, with the caveat that a large glycoprotein is harder to characterise.
Follistatin 344 in the catalogue
We hold every lot to 99% by HPLC and keep the matching paperwork on file.
Where Follistatin 344 fits in
Background reading, if the ground here felt unfamiliar.
About Follistatin 344
The questions that reach our support desk.